T Ochsenkuhn

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. ncbi [Pathogenesis and epidemiology of sigmoid diverticulosis]
    T Ochsenkuhn
    Medizinische Klinik II, Klinikum Grosshadern, LMU Munchen, Marchioninistrasse 15, 81375 München
    Chirurg 73:665-9. 2002
  2. ncbi [Inflammatory bowel diseases (IBD) -- critical discussion of etiology, pathogenesis, diagnostics, and therapy]
    T Ochsenkuhn
    Medizinische Klinik II, Klinikum der Universitat Munchen Grosshadern, Munich
    Radiologe 43:1-8. 2003
  3. ncbi Does ursodeoxycholic acid change the proliferation of the colorectal mucosa?. A randomized, placebo-controlled study
    Thomas Ochsenkuhn
    Department of Medicine II, Klinikum Grosshadern, Munich, Germany
    Digestion 68:209-16. 2003
  4. ncbi Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study
    J Seiderer
    Department of Internal Medicine II, University Hospital Munich Grosshadern, Munich, Germany
    Aliment Pharmacol Ther 25:787-96. 2007
  5. ncbi The role of the selenoprotein S (SELS) gene -105G>A promoter polymorphism in inflammatory bowel disease and regulation of SELS gene expression in intestinal inflammation
    J Seiderer
    Department of Internal Medicine II Grosshadern, University of Munich, Marchioninistrasse 15, D 81377 Munich, Germany
    Tissue Antigens 70:238-46. 2007
  6. ncbi Low frequency of colorectal dysplasia in patients with long-standing inflammatory bowel disease colitis: detection by fluorescence endoscopy
    T Ochsenkuhn
    Department of Medicine II, Klinikum Grosshadern, University of Munich, Germany
    Endoscopy 38:477-82. 2006
  7. ncbi Crohn disease of the small bowel proximal to the terminal ileum: detection by MR-enteroclysis
    T Ochsenkuhn
    Department of Medicine II, Institute of Clinical Radiology, Klinikum Grosshadern, University of Munich, Germany
    Scand J Gastroenterol 39:953-60. 2004
  8. ncbi The role of fatty acid hydrolase gene variants in inflammatory bowel disease
    M Storr
    Department of Medicine II Grosshadern, University of Munich, Munich, Germany
    Aliment Pharmacol Ther 29:542-51. 2009
  9. ncbi The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn's disease
    D Thalmaier
    Department of Medicine II Grosshadern, University of Munich, Munich, Germany
    Aliment Pharmacol Ther 24:1105-15. 2006
  10. ncbi [MRI in Crohn's disease after transduodenal contrast administration using negative oral MRI contrast media]
    N Holzknecht
    Institut fur Klinische Radiologie, Klinikum Grosshadern, Ludwig Maximilians Universitat Munchen, Munich
    Radiologe 43:43-50. 2003

Collaborators

Detail Information

Publications10

  1. ncbi [Pathogenesis and epidemiology of sigmoid diverticulosis]
    T Ochsenkuhn
    Medizinische Klinik II, Klinikum Grosshadern, LMU Munchen, Marchioninistrasse 15, 81375 München
    Chirurg 73:665-9. 2002
    ..Intestinal disturbances of innervation and motility also contribute to the formation of diverticula. The term "hypersegmentation" is an attempt to combine these factors into a single pathogenetic model...
  2. ncbi [Inflammatory bowel diseases (IBD) -- critical discussion of etiology, pathogenesis, diagnostics, and therapy]
    T Ochsenkuhn
    Medizinische Klinik II, Klinikum der Universitat Munchen Grosshadern, Munich
    Radiologe 43:1-8. 2003
    ..The basic understanding of IBD,which is necessary for efficient diagnostic and therapeutic concepts is reviewed...
  3. ncbi Does ursodeoxycholic acid change the proliferation of the colorectal mucosa?. A randomized, placebo-controlled study
    Thomas Ochsenkuhn
    Department of Medicine II, Klinikum Grosshadern, Munich, Germany
    Digestion 68:209-16. 2003
    ..To explain this, a reduced proliferation of the colorectal mucosal proliferation was suggested. We, therefore, examined the influence of UDCA on the proliferation of normal colorectal mucosa in humans...
  4. ncbi Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study
    J Seiderer
    Department of Internal Medicine II, University Hospital Munich Grosshadern, Munich, Germany
    Aliment Pharmacol Ther 25:787-96. 2007
    ....
  5. ncbi The role of the selenoprotein S (SELS) gene -105G>A promoter polymorphism in inflammatory bowel disease and regulation of SELS gene expression in intestinal inflammation
    J Seiderer
    Department of Internal Medicine II Grosshadern, University of Munich, Marchioninistrasse 15, D 81377 Munich, Germany
    Tissue Antigens 70:238-46. 2007
    ....
  6. ncbi Low frequency of colorectal dysplasia in patients with long-standing inflammatory bowel disease colitis: detection by fluorescence endoscopy
    T Ochsenkuhn
    Department of Medicine II, Klinikum Grosshadern, University of Munich, Germany
    Endoscopy 38:477-82. 2006
    ..We combined this technique with random biopsies to prospectively evaluate the occurrence of dysplasias in patients with long-standing IBD...
  7. ncbi Crohn disease of the small bowel proximal to the terminal ileum: detection by MR-enteroclysis
    T Ochsenkuhn
    Department of Medicine II, Institute of Clinical Radiology, Klinikum Grosshadern, University of Munich, Germany
    Scand J Gastroenterol 39:953-60. 2004
    ..Hence, we applied MR-enteroclysis to assess the percentage of patients with small-bowel inflammation proximal to the terminal ileum among patients with CD and abdominal pain...
  8. ncbi The role of fatty acid hydrolase gene variants in inflammatory bowel disease
    M Storr
    Department of Medicine II Grosshadern, University of Munich, Munich, Germany
    Aliment Pharmacol Ther 29:542-51. 2009
    ..Recent studies suggest a role for the endocannabinoid system, including fatty acid amide hydrolase (FAAH), in intestinal inflammation...
  9. ncbi The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn's disease
    D Thalmaier
    Department of Medicine II Grosshadern, University of Munich, Munich, Germany
    Aliment Pharmacol Ther 24:1105-15. 2006
    ..Serum C-reactive protein (CRP) levels influence the response to anti-tumour necrosis factor (TNF) therapies...
  10. ncbi [MRI in Crohn's disease after transduodenal contrast administration using negative oral MRI contrast media]
    N Holzknecht
    Institut fur Klinische Radiologie, Klinikum Grosshadern, Ludwig Maximilians Universitat Munchen, Munich
    Radiologe 43:43-50. 2003
    ..To compare the efficacy and quality of conventional and MR enteroclysis with different filling methods regarding the assessment of extension and extraluminal manifestations in Crohn's disease...